ESMO 2017 Congress: Integrating science into oncology for a better patient outcome
Don't miss ESMO 2017: the place to be for the latest news in oncology! The count of submitted abstracts this year has marked a 13% increase since ESMO 2016, with 3,250 abstracts received, 92 of them earmarked for submission as Late Breaking Abstracts.
"The collaboration between clinicians and researchers is vital in an era requiring a deep understanding of the molecular biology underlying the development of cancer. ESMO 2017 will be a truly integrated congress, bringing together researchers and clinicians to help bridge the gap between innovation and clinical implementation, thanks to the partnership with the European Association for Cancer Research (EACR). This collaboration enriches us by facilitating a united approach to cancer research, treatment and care," said Fortunato Ciardiello, ESMO President.
With continuing growth over the past six years, the ESMO Congress is confirmed as the leading international oncology event in Europe.
The USA, Spain, Japan, France and Italy were the top five submitters, showing that ESMO 2017 Congress is a truly international convention, where professionals come to learn about the latest advances in cancer, discuss clinical challenges and share best practices to improve patient treatment and care.
More than 22,000 participants from all over the world are expected in Madrid, from professionals representing various oncology disciplines to healthcare policy makers, and from patient advocates and pharmaceutical companies to international media.
Congress programme highlights
The ten research fields with most submissions were:
- Upper gastrointestinal tumours and colorectal cancer, a field with many unmet medical needs
- Identification and study of biomarkers, a growing area of research, due to the need to target medicines to offer them to those who can benefit for better targeted treatment
- Metastatic non-small-cell lung cancer, under the spotlight for some time now as one of the most thriving fields in oncology
- Genitourinary tumours: with exciting studies on advances in immunology
- Early and metastatic breast cancer, still the leading cause of death among women aged 20 to 59 years, worldwide (1)
- Gynaecological cancers, with many unmet needs in ovarian cancer. Cervical cancer is the second most common type of cancer in women worldwide (1)
- Immunotherapy of cancer, including future perspectives, new biomarkers for response to immunotherapy and management of toxicities
Topics to look out for:
- Basic research: understanding of the molecular biology underlying the development of cancer is a first important step to equip clinicians to improve outcomes for patients
- Translational research: the field of the future, applying findings from basic science to medical practice for meaningful outcomes
- Supportive care: advances in patient-centred care to improve quality of life from diagnosis and throughout the continuum of treatment
- Health policy: sessions focusing on critical issues impacting doctors and patients alike, including, among others, cancer medicine shortages in Europe, equal access to anti-cancer drugs, use of Big Data and different approaches to qualify clinical benefit in oncology
- Patient advocacy track: cancer patients provide valuable input into healthcare decision-making processes and scientific research
Also, keep an eye on the Keynote Lectures: these must-attend sessions give delegates the full picture regarding the evolution of cancer research and patient care, reaching beyond individual disease types to offer thought-provoking interdisciplinary discussion including:
- Clinical implications of tumour evolution, on 9 Sept at 08:15
- Coping with escalating healthcare costs in 2017 and beyond, on 10 Sept at 08:15
- Does immunotherapy cure advanced cancer? On 11 Sept at 08:15
The full ESMO 2017 Congress programme is available here:
Abstract titles will be published around mid-July.
ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.
Media representatives are required to observe and abide by the ESMO 2017 Media Policy
To register for the event, please fill out the Complimentary
Media Registration Form: http://www.esmo.org/Conferences/ESMO-2017-Congress/Press-Media
Media registration in advance is strongly recommended (deadline: 04 September 2017).
A fully equipped ESMO Press Centre will be available to registered journalists, including a press room with technical facilities (computers, wi-fi internet, telephones, photocopier, etc.), interview rooms and storage cabinets. On-site staff will be ready to assist and facilitate one-on-one interviews with researchers and key opinion leaders throughout the Congress.
ESMO Press Programme
The official ESMO 2017 Press Programme is being developed and will be confirmed after review and acceptance of submitted abstracts. Details will be progressively uploaded here: http://www.esmo.org/Conferences/ESMO-2017-Congress/Programme
Meeting venue and accommodation
The ESMO 2017 Congress will take place at the Feria de Madrid, close to Barajas airport, at the Campo de las Naciones Metro station (Line 8). The Feria de Madrid is conveniently located for both the airport (6 kilometres) and the city centre (15 kilometres). Further information can be found here: http://www.ifema.es/Institucional_06/informacion_general/como_llegar/index.htm
IFEMA, Feria de Madrid
Avda. del Partenón, 5
28042 Madrid, Spain
As Madrid is a highly popular tourist destination, we advise you to book your hotel accommodation as soon as possible.
We look forward to welcoming you in Madrid!
The ESMO Press Office Team
Tel: +41 (0)91 973 19 04
1 World Health Organization factsheets on women's health, 2013: http://www.who.int/mediacentre/factsheets/fs334/en/